Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
By Xueling Wu, Zhi-yong Yang, Yuxing Li, Carl-Magnus Hogerkorp, William R. Schief, M. Seaman, T. Zhou, S. Schmidt, Lan Wu, Ling Xu and 14 more. Science, 2010
1,825 citations recorded by the source corpus.
Designer Anti-HIV Developing a protective HIV vaccine remains a top global health priority. One strategy to identify potential vaccine candidates is to isolate broadly neutralizing antibodies from infected individuals and then attempt to elicit the same antibody response through vaccination (see the Perspective by Burton and Weiss). Wu et al. (p. 856, published online 8 July) now report the identification of three broadly neutralizing antibodies, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike. Zhou et al. (p. 811, published online 8 July) analyzed the crystal structure for one of these antibodies, VRC01, in complex with an HIV-1 gp120. VRC01 focuses its binding onto a conformationally invariant domain that is the site of initial CD4 attachment, which allows the antibody to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. The epitopes recognized by these antibodies suggest potential immunogens that can inform vaccine design. A human antibody achieves broad neutralization by binding the viral site of recognition for the primary host receptor, CD4. Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1–infected individuals, but the virologic basis of their neutralization remains poorly understood. We used knowledge of HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for the structurally conserved site of initial CD4 receptor binding. These probes were used to identify sera with NAbs to the CD4-binding site (CD4bs) and to isolate individual B cells from such an HIV-1–infected donor. By expressing immunoglobulin genes from individual cells, we identified three monoclonal antibodies, including a pair of somatic variants that neutralized over 90% of circulating HIV-1 isolates. Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design.
Subfields: Immunology, Radiology, Nuclear Medicine and Imaging, Virology
View Paper: https://www.semanticscholar.org/paper/6a75ca832fd5581920adf62bbf5a1fdbb6efcbc7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Radiology, Nuclear Medicine and Imaging
In Virology
Citations in the corpus
- Molecular Evolution of Broadly Neutralizing Llama Antibodies to the CD4-Binding Site of HIV-1 (2014, background): “In contrast to the ability of these VHH to bind RSC3 this argues against their being similar to VRC01.”
- Glycan-Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies (2018, positive): “Single B cell RT-PCR, gene amplification, cloning and mutation analysis of cloned IgH and IgL chains Reverse transcription and subsequent PCR amplification of heavy and light chain variable genes were performed using SuperScript III (Life Technologies) as previously described (Tiller et al., 2009; W”
- Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site (2015, positive): “The VRC01class of antibodies that bind the CD4-binding site of the envelope of human immunodeficiency virus 1 (HIV-1) potently neutralize >90% of circulating viral strains regardless of their sequence variability (Wu et al., 2010; Zhou et al., 2010).”
- Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys (2013, positive): “A series of broad and potent HIV-1 Env-specific mAbs have recently been isolated 1,2 and have been shown to target the CD4 binding site 3–7 , the V1/V2 loops 8,9 , the V3/V4 loops and N332 glycans 10–13 , and the membrane proximal external region (MPER) 14 .”
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding (2020, positive): “Second, our maps show which mutations can be introduced into the RBD without disrupting key biochemical phenotypes, thereby opening the door to resurfacing immunogens to focus antibodies on specific epitopes (Duan et al., 2018; Eggink et al., 2014; Jardine et al., 2016; Kulp et al., 2017; Weidenbach”
- Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization (2018, background): “Monoclonal anti-HIV-1 Env VRC01 Produced in house (Wu et al., 2010) RRID: AB_2491019”
- Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles (2016, positive): “A 60-meric LS nanoparticle presenting an engineered gp120 core lacking variable loops (V1V2 and V3) and inner domain has been used to target the germline precursors of VRC01 (refs 37,38), a CD4-binding site (CD4bs)-directed bNAb 51 .”